type
ii
felin
infecti
periton
viru
fipv
infect
felin
macrophag
enhanc
monoclon
antibodi
mab
protein
fipv
antibodydepend
enhanc
ade
activ
increas
mab
show
neutral
activ
felin
kidney
cell
suggest
distinct
correl
ade
activ
neutral
activ
close
associ
enhanc
neutral
epitop
obstacl
develop
vaccin
contain
neutral
epitop
without
enhanc
epitop
studi
immun
cat
cell
lysat
recombin
baculovirusexpress
n
protein
type
fipv
strain
adjuv
investig
prevent
effect
progress
fip
cat
immun
vaccin
produc
antibodi
fipv
virionderiv
n
protein
produc
virusneutr
antibodi
delay
type
hypersensit
skin
respons
n
protein
observ
vaccin
cat
show
cell
mediat
immun
fipv
antigen
induc
vaccin
cat
challeng
high
dose
heterolog
fipv
surviv
rate
surviv
rate
control
group
immun
cellderiv
antigen
studi
show
immun
cell
lysat
baculovirusexpress
n
protein
effect
prevent
progress
fip
without
induc
ade
fipv
infect
cat
felin
infecti
periton
fip
virusinduc
chronic
progress
immunologicallymedi
usual
fatal
diseas
domest
wild
felida
caus
agent
diseas
fip
viru
fipv
belong
famili
coronavirida
prevent
fip
variou
vaccin
virulenceattenu
live
inactiv
fipv
vaccin
investig
vaccin
exhibit
suffici
effect
vaccin
rather
enhanc
onset
fip
wood
pedersen
pedersen
et
al
pedersen
black
pedersen
et
al
barlough
et
al
pedersen
stoddart
et
al
intraperiton
inocul
virul
fipv
induc
sever
clinic
sign
antifipv
antibodyposit
kitten
kitten
receiv
passiv
immun
serum
purifi
igg
antibodyposit
cat
antibodyneg
kitten
pedersen
boyl
weiss
scott
antibodyinduc
enhanc
fipv
infect
seriou
obstacl
prevent
fip
vaccin
gener
macrophag
play
import
role
nonspecif
defens
viral
infect
howev
also
known
virus
bound
antibodi
invad
macrophag
via
fc
region
antibodi
fc
gamma
receptor
macrophag
eventu
antibodi
lead
enhanc
infect
phenomenon
call
antibodydepend
enhanc
ade
viru
infect
halstead
orourk
macrophag
known
one
target
cell
fipv
report
ade
fipv
infect
induc
mechan
hohdatsu
et
al
corapi
et
al
olsen
et
al
hohdatsu
et
al
fipv
consist
three
major
protein
nucleocapsid
n
protein
transmembran
protein
peplom
protein
among
protein
neutral
ade
epitop
mainli
present
protein
hohdatsu
et
al
corapi
et
al
olsen
et
al
previous
report
vitro
fipv
infect
felin
alveolar
macrophag
enhanc
monoclon
antibodi
mab
protein
fipv
ade
activ
increas
mab
show
neutral
activ
felin
kidney
cell
suggest
distinct
correl
ade
activ
neutral
activ
olsen
et
al
hohdatsu
et
al
close
associ
enhanc
neutral
epitop
obstacl
develop
vaccin
contain
neutral
epitop
without
enhanc
epitop
although
recombin
vaccin
prepar
insert
gene
encod
protein
vaccinia
viru
vaccin
prevent
fipv
infect
rather
enhanc
onset
fip
vennema
et
al
effect
recombin
vaccin
prepar
insert
gene
encod
fipv
n
protein
vaccinia
viru
vennema
et
al
raccoon
poxviru
wasmoen
et
al
dna
vaccin
contain
gene
n
gene
glansbeek
et
al
fipv
infect
investig
among
studi
vaccin
use
recombin
raccoon
poxviru
express
n
gene
rrcnvfipvn
report
wasmoen
et
al
effect
lowdos
fipv
challeng
howev
sinc
challeng
felin
enter
coronaviru
fecv
oral
immun
rrcnvfipvn
studi
show
effect
vaccin
alon
moreov
vaccin
recombin
live
vaccin
field
applic
requir
resolut
mani
problem
includ
safeti
temperaturesensit
mutant
strain
fipv
produc
appear
safe
efficaci
low
dose
homolog
experiment
challeng
christianson
et
al
gerber
et
al
howev
still
controversi
safeti
efficaci
vaccin
protect
may
depend
strain
dose
challeng
viru
scott
et
al
mcardl
et
al
vaccin
cat
show
ade
challeng
high
dose
heterolog
viru
strain
scott
et
al
therefor
vaccin
suffici
safe
effect
fipv
infect
present
studi
immun
cat
cell
lysat
baculovirusexpress
n
protein
type
fipv
strain
adjuv
investig
prevent
effect
onset
fip
vaccin
cat
produc
antibodi
n
protein
produc
virusneutr
antibodi
cell
mediat
immun
consid
play
import
role
prevent
onset
fip
delay
type
hypersensit
dth
skin
respons
n
protein
observ
vaccin
cat
vaccin
cat
challeng
high
dose
heterolog
fipv
onset
fip
prevent
without
induct
ade
surviv
rate
spodoptera
frugiperda
sf
cell
grown
monolay
c
medium
contain
fetal
calf
serum
fc
uml
penicillin
gml
streptomycin
feli
catu
whole
fetu
fcwf
cell
cultur
monolay
c
humidifi
atmospher
co
eagl
minimum
essenti
medium
contain
leibovitz
medium
fetal
calf
serum
fc
uml
penicillin
gml
streptomycin
type
fipv
strain
type
ii
fipv
strain
grown
cell
c
fipv
strain
isol
laboratori
fipv
strain
suppli
dr
mc
horzinek
state
univers
utrecht
netherland
recombin
baculoviru
express
fipv
n
protein
grown
cell
c
antifelin
coronaviru
fcov
antibodyneg
specif
pathogenfre
cat
age
month
use
cat
maintain
temperaturecontrol
isol
facil
genom
rna
extract
fipv
strain
infect
cultur
fluid
revers
transcript
rt
genom
rna
amplif
cdna
polymeras
chain
reaction
pcr
carri
use
standard
techniqu
dna
thermal
cycler
rtpcr
primer
design
cover
entir
bp
fipv
strain
gene
access
pcr
product
clone
plasmid
escherichia
coli
strain
transfect
recombin
plasmid
dna
cultur
white
coloni
grown
select
recombin
bacmid
dna
recov
cell
transfect
recombin
bacmid
dna
use
cell
fectin
cultur
supernat
use
experi
recombin
baculovirusexpress
fipv
n
protein
cell
cultur
day
inocul
recombin
baculoviru
absorpt
h
serumfre
medium
ad
cell
cell
cultur
c
cultur
h
infect
cell
recov
wash
pb
one
millilit
rsb
buffer
contain
nacl
mgcl
trishcl
ph
ad
cell
cell
suspens
kept
c
min
occasion
shake
cell
centrifug
g
min
precipit
resuspend
pb
use
recombin
n
protein
felin
inactiv
trival
vaccin
felidovac
pcr
intervet
netherland
commerci
avail
japan
ad
recombin
n
protein
adjuv
felin
inactiv
trival
vaccin
contain
aluminum
hydroxid
gel
adjuv
specif
recombin
n
protein
amount
antigen
measur
enzymelink
immunosorb
assay
elisa
western
immunoblot
use
antifipv
monoclon
antibodi
elisa
western
immunoblot
perform
method
hohdatsu
et
al
cellderiv
antigen
prepar
control
antigen
treatment
cell
day
cultur
recoveri
recombin
n
protein
detergentdisrupt
virion
fipv
strain
purifi
discontinu
sucros
densiti
gradient
ultracentrifug
separ
sdspage
posit
correspond
molecular
weight
n
protein
estim
posit
marker
protein
gel
posit
recov
n
protein
electrophoret
elut
recov
gel
use
protein
elut
apparatu
maxyield
gp
atto
corp
japan
specif
n
protein
investig
use
mab
recogn
fipv
n
protein
hohdatsu
et
al
electrophoret
purifi
n
protein
use
antigen
detect
antibodi
elisa
measur
dth
skin
respons
evalu
efficaci
recombin
n
protein
vaccin
vaccin
challeng
experi
repeat
twice
eight
spf
cat
age
month
eight
spf
cat
age
month
use
first
second
experi
respect
experi
four
cat
subcutan
vaccin
three
time
interv
challeng
control
four
cat
receiv
subcutan
administr
cellderiv
antigen
prepar
recombin
n
protein
describ
adjuv
four
week
third
vaccin
cat
challeng
oronas
tcid
fipv
strain
cat
observ
daili
clinic
diseas
sign
bodi
temperatur
bodi
weight
measur
everi
day
second
experi
oropharyng
swab
obtain
everi
day
viru
isol
serum
collect
everi
day
detect
antifipv
antibodi
antibodi
respons
fipv
nucleocapsid
detect
elisa
use
n
protein
electrophoret
purifi
detergentdisrupt
fipv
virion
fipvneutr
activ
heatinactiv
cat
sera
determin
describ
previous
use
cell
micropl
assay
hohdatsu
et
al
antibodi
titer
express
reciproc
highest
dilut
serum
complet
inhibit
viral
cytopath
effect
cellmedi
immun
respons
fipv
antigen
measur
intraderm
skin
test
use
n
protein
electrophoret
purifi
detergentdisrupt
fipv
virion
left
later
abdomen
vaccin
cat
shave
disinfect
ethanol
ml
gml
antigen
pb
intraderm
inject
skin
site
diamet
swell
inject
site
measur
h
inject
use
calip
specif
recombin
baculovirusexpress
fipv
n
protein
investig
elisa
western
immunoblot
use
mab
elisa
twofold
serial
dilut
recombin
n
protein
immobil
flat
bottom
microelisa
plate
react
mab
protein
mab
protein
mab
n
protein
shown
fig
recombin
n
protein
react
react
recogn
n
protein
similarli
recombin
n
protein
react
western
immunoblot
specif
band
detect
posit
correspond
kda
amount
recombin
n
protein
antigen
per
dose
vaccin
measur
western
immunoblot
use
mab
amount
antigen
detect
posit
band
dilut
u
per
dose
western
immunoblot
contain
one
dose
vaccin
fig
humor
cellmedi
immun
respons
fipv
antigen
investig
cat
immun
recombin
n
protein
vaccin
control
cat
increas
elisa
valu
fipv
virionderiv
n
protein
observ
week
third
immun
vaccin
cat
first
second
experi
fig
howev
neutral
antibodi
titer
homolog
strain
challeng
viru
strain
increas
even
third
immun
titer
lower
vaccin
cat
control
cat
immun
cellderiv
antigen
neither
elisa
valu
neutral
antibodi
titer
increas
three
week
third
immun
ml
fipv
virionderiv
n
protein
intracutan
inject
vaccin
cat
induct
dth
skin
respons
fipv
antigen
investig
four
vaccin
anim
first
experi
swell
n
proteininject
skin
site
observ
h
swell
persist
h
cat
swell
observ
pbsinject
skin
site
second
experi
swell
also
observ
n
proteininject
skin
site
four
vaccin
cat
cat
second
experi
transient
swell
observ
pbsinject
skin
site
h
fig
show
diamet
swell
measur
use
calip
cat
first
second
experi
four
week
third
vaccin
cat
challeng
oronas
tcid
fipv
strain
antibodi
respons
n
protein
neutral
antibodi
titer
challeng
viru
chang
bodi
weight
surviv
curv
shown
tabl
fig
fig
respect
vaccin
cat
elisa
valu
n
protein
began
increas
day
challeng
antibodi
respond
earlier
control
cat
fig
antichalleng
viru
strain
neutral
antibodi
product
convert
posit
day
challeng
vaccin
control
group
show
signific
differ
two
group
tabl
sampl
obtain
oropharyng
swab
collect
everi
day
inocul
cell
isol
viru
viru
isol
day
challeng
cat
vaccin
control
group
show
signific
differ
viru
isol
first
experi
bodi
weight
gradual
decreas
sever
clinic
diseas
develop
cat
control
group
anim
euthan
day
fipv
challeng
postmortem
examin
find
consist
system
patholog
fip
diseas
contrast
vaccin
group
cat
develop
fip
three
anim
develop
clinic
sign
fip
observ
period
fig
similarli
second
experi
three
four
anim
control
group
develop
system
patholog
fip
diseas
day
fipv
challeng
euthan
vaccin
group
cat
develop
fip
three
anim
toler
challeng
fig
combin
result
first
second
experi
surviv
rate
immun
control
group
respect
surviv
rate
analyz
use
test
signific
differ
p
studi
confirm
immun
cat
baculovirusexpress
n
protein
effect
prevent
progress
fip
follow
highdos
tcid
fipv
challeng
cat
immun
vaccin
inhibit
fip
progress
attain
surviv
rate
describ
introduct
wasmoen
et
al
report
cat
infect
fecv
immun
recombin
racoon
poxvuri
express
n
gene
onset
fip
inhibit
lowdos
virul
fipv
challeng
tcid
howev
studi
show
effect
vaccin
alon
studi
first
report
recombin
n
protein
alon
attain
surviv
rate
highdos
virul
fipv
challeng
although
use
type
fipv
strain
recombin
n
protein
antigen
vaccin
also
inhibit
onset
fip
follow
challeng
type
ii
fipv
strain
still
unclear
whether
immun
effect
serotyp
fipv
challeng
sinc
pathogen
oronas
challeng
strain
may
natur
rout
infect
weak
vaccin
effect
strain
could
evalu
use
onset
fip
index
studi
sinc
type
fipvfecv
infect
domin
field
hohdatsu
et
al
necessari
investig
protect
effect
type
fipv
infect
futur
howev
amino
acid
sequenc
n
protein
conserv
rel
well
among
fipv
strain
higher
homolog
motokawa
et
al
infect
type
fipv
may
control
use
protein
enhanc
epitop
present
n
protein
report
ade
observ
studi
confirm
protein
safe
contrast
gene
analysi
protein
shown
amino
acid
sequenc
type
ii
fipv
differ
homolog
motokawa
et
al
suggest
difficult
achiev
effect
infect
two
type
fipv
protein
select
vaccin
antigen
differ
viru
isol
oropharyng
swab
collect
virul
fipv
challeng
vaccin
control
cat
second
experi
show
fipv
infect
prevent
howev
virul
fipv
challengeinduc
progress
fip
prevent
vaccin
cat
cellular
immun
consid
import
prevent
progress
fip
pedersen
vaccin
cat
develop
dthskin
respons
n
protein
suggest
cell
mediat
immun
fipv
antigen
induc
cox
report
strong
dth
skin
respons
fipv
antigen
induc
cat
surviv
fipv
infect
fipv
challengeexposur
although
data
shown
observ
dth
respons
virionderiv
n
protein
antifcov
antibodyneg
spf
cat
cat
develop
fip
cat
toler
fipv
challengeexposur
fecvinfect
cat
exhibit
posit
reaction
find
strongli
suggest
dth
respons
fipv
associ
increas
resist
diseas
gener
inactiv
vaccin
induc
humor
immun
vaccin
recogn
exogen
protein
induct
cellular
immun
difficult
howev
found
antigen
incorpor
immunostimul
complex
encapsul
certain
liposom
stimul
cytotox
lymphocyt
ctl
immun
takahashi
et
al
reddi
et
al
addit
kovacsovicsbankowski
et
al
report
solubl
antigen
conjug
bead
effici
induc
ctl
immun
immun
solubl
antigen
alon
consid
convers
solubl
insolubl
antigen
bind
bead
increas
phagocytosi
antigen
antigenpres
cell
apc
result
activ
mhc
class
present
pathway
exogen
protein
recombin
baculovirusexpress
fipv
n
protein
use
studi
insolubl
antigen
prepar
follow
recombin
baculovirusinfect
cell
disrupt
rsb
buffer
contain
centrifug
g
min
precipit
resuspend
pb
use
insolubl
n
protein
vaccin
antigen
may
induc
cellular
immun
includ
dth
respons
effici
antigen
prepar
describ
may
contain
baculovirusderiv
antigen
recent
report
baculoviru
could
induc
nonspecif
antivir
effect
mammal
gronowski
et
al
therefor
possibl
baculovirusderiv
antigen
synerget
effect
success
protect
vaccin
use
studi
contain
high
concentr
recombin
n
protein
u
western
immunoblot
prevent
onset
fip
without
induc
ade
highdos
fipv
challeng
vaccin
may
effect
prevent
onset
fip
follow
lowdos
viru
challeng
close
spontan
infect
